李曄雄，博士，籍貫湖南，腫瘤放療專家。中國醫學科學院協和醫科大學腫瘤醫院教授、主任醫師，博士生導師。1984年湖南醫科大學醫療系畢業獲得學士學位，1990年獲中國協和醫科大學放射腫瘤學碩士學位，1997年獲瑞士洛桑大學放射腫瘤學博士學位，1998年在美國德克薩斯大學M.D. Anderson癌癥中心從事博士后研究。2003年起聘任正高，2020年為協和長聘教授。2000年任科主任。一直從事放射腫瘤學臨床和轉化研究。

主要研究領域為惡性腫瘤的放療，開展和應用最先進放療技術，改進治療方法，著重探索淋巴瘤臨床病理和生物學特征，建立風險分層治療原則和放療指南，建立乳腺癌術后短療程大分割照射方案等，居國際領先水平。

爆草黑丝美女|韩国19禁无遮挡啪啪无码网站|91精品国产自产精品男人的天堂|sm鞭打高潮喷水抽搐调教玩弄|果冻在线|日本大尺度吃奶呻吟视频|久久久久黄片|北条麻妃av免费观看|中文字幕一区二区人妻|亚洲最大天堂无码精品区,日韩 欧美 国产精品,国产肉丝袜在线观看,最爽无遮挡行房视频,成人H视频在线观看,糖心vlog冉冉,蜜桃产品一二三产区

1. Jin J#*, Tang Y#, Hu C, Jiang LM, Jiang J, Li N, Liu WY, Chen SL, Li H, Lu NN, Cai Y, Li YH, Zhu Y, Cheng GH, Zhang HY, Wang X, Zhu SY, Wang J, Li GF, Yang JL, Zhang K, Chi Y, Yang L, Zhang HZ, Zhou ZX, Zhou AP, Zou SM, Fang H, Wang SL, Zhang HZ*, Wang XS*, Wei LC*, Wang WL*, Liu SX*, Gao YH*, Li YX*. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022, 40:1681-1692. (IF=50.717, PIII)

2. Chen B#, Wu JX#, Cheng SH, Wang LM, Rong WQ,Wu F, Wang SL, Jin J, Liu YP, Song YW, Ren H, Fang H, Tang Y, Li N, Li YX*, Wang WH*. Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma. Hepatol. 2021, 74(5):2595-2604. (IF=17.298)

3. Wang SL# Fang F#, Hu C, Song YW, Wang WH, Jin J, Liu YP, Ren H, Liu J, Li GF, Du XH, Hui X, Tang Y, Jing H, Ma YC, Huang Z, Chen B, Tang Y, Li N, Lu NN, Qi SN, Yang Y, Sun GY, Liu XF, Li YX*. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicentre randomized controlled trial from China. J Clin Oncol. 2020, 38:3604-3614. (IF=44.544, PIII, R)

4. Wang SL#, Fang H#, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, Li N, Lu NN, Tang Y, Tang Y, Qi SN, Sun GY, Peng R, Li S, Chen B, Yang Y, Li YX*. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for high-risk breast cancer patients: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019, 20:352-360. (IF=32.277, PIII, ESI, R)

5. Yang Y#, Cao JZ#, Lan SM, Wu JX, Wu T, Zhu SY, Qian LT, Hou XR, Zhang FQ, Zhang YJ, Zhu Y, Xu LM, Yuan ZY, Qi SN, and Li YX*. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type NK/T-cell lymphoma. JAMA Oncol. 2017, 3(1):83-91. (IF=16.559)

6. Yang Y#, Zhu Y#, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, Wu JX, Wang W, Wu T, Lu B, Zhu SY, Qian LT, Zhang FQ, Hou XR, and Li YX*. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015, 126(12):1424-1432. (IF=9.762)

7. Wang ZY#, Liu QF, Wang H, Jin J, Wang WH, Wang SL, Song YW, Liu YP, Fang H, Ren H, Wu RY, Chen B, Zhang XM, Lu NN, Zhou LQ, Li YX*. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extra nodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012, 120(10):2003-2010. (IF=10.337)

8. Wang ZY#, Li YX*, Wang WH, Jin J, Wang H, Song YW, Liu QF, Wang SL, Liu YP, Qi SN, Fang H, Liu XF, and Yu ZH. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood. 2009, 114(23):4771-4776. (IF=10.566, R)

9. Li YX*#, Fang H, Liu QF, Lu J, Qi SN, Wang H, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Feng XL, and Yu ZH. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood. 2008, 112(8):3057-3064. (IF=10.466, R)

10. Li YX*#, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, Lu N, and Yu ZH. Radiotherapy as primary treatment for stage IE and IIE nasal NK/T-cell lymphoma. J Clin Oncol. 2006, 24(1):181-189. (IF=10.863, C100, R)